RO 7759065
Alternative Names: RO-7759065Latest Information Update: 03 Sep 2024
At a glance
- Originator Genentech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Aug 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (Parenteral)
- 15 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA (Parenteral)
- 17 Jul 2024 Preclinical trials in Solid tumours in USA (unspecified route), prior to July 2024